Havisure: India's First Indigenously Developed Hepatitis A Vaccine

Indian Immunologicals Ltd (IIL), a subsidiary of the National Dairy Development Board (NDDB), has made a significant stride in the nation's healthcare sector with the introduction of Havisure, the first indigenously developed Hepatitis A vaccine. This launch marks a pivotal advancement in India's relentless fight against Hepatitis A, a common viral infection primarily transmitted through contaminated food or water.

An Indigenously Developed Vaccine

India's first homegrown Hepatitis A vaccine, Havisure, comes as a response to the growing demand for a solution against the viral infection. The vaccine, developed by IIL, has gained approval from the Drug Controller General of India. It is designed for routine immunization in children and individuals who are at risk of exposure or planning to travel to regions with high Hepatitis A prevalence.

Clinical Trials and Efficacy

The development of Havisure has been backed by extensive clinical trials conducted across eight centers in India. The trials have demonstrated the safety and efficacy of the vaccine, making it comparable to leading vaccines available on the global market. The two-dose vaccine regimen involves the administration of the initial dose to individuals above 12 months of age, followed by a second dose at least six months after the first.

Collaboration for Awareness

As part of its initiative, IIL is collaborating with healthcare professionals, corporate hospitals, and government agencies to promote awareness about Hepatitis A and the importance of vaccination. This broad-based collaboration aims to ensure that the benefits of Havisure reach as many people as possible, playing a crucial role in preventing the spread of Hepatitis A in India.